Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.
Also called NCT06616961
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 480 participants
- Sponsor
- Popular Medical College Hospital
- Registry
-
NCT06616961
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Bangladesh
- Registry status
- Unknown status
Technical summary
Registry record NCT06616961. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-01 (anticipated); primary completion 2025-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
- Condition
- Obesity
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- Semaglutide Pen
- Lead sponsor
- Popular Medical College Hospital
- Collaborator
- Pi Research and Development Center, Bangladesh
- Collaborator
- Incepta Pharmaceuticals Ltd
Record details
- Record id
cardio:ct-nct06616961- Content hash
e59bcadce6027d73d2aed89f535916bd3f4042059695656107794562b519e83b